Peptidomimetic Src/pretubulin inhibitor KX-01 alone and in combination with paclitaxel suppresses growth, metastasis in human ER/PR/HER2-negative tumor xenografts

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 1936-1947

  Anbalagan, Muralidharan ^a   Ali, Alaa ^a   Jones, Ryan K ^a   Marsden, Carolyn G ^a   Sheng, Mei ^a   Carrier, Latonya ^a   Bu, Yahao ^b   Hangauer, David ^b   Rowan, Brian G ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DASATINIB; FOCAL ADHESION KINASE; KI 67 ANTIGEN; KX 01; PACLITAXEL; PROTEIN TYROSINE KINASE INHIBITOR; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG METASTASIS; METASTASIS; MICROMETASTASIS; MICROTUBULE; MICROVASCULATURE; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR VOLUME; TUMOR XENOGRAFT;

ACETAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DRUG SYNERGISM; ESTROGEN RECEPTOR ALPHA; FEMALE; FOCAL ADHESION KINASE 1; HUMANS; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM MICROMETASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PACLITAXEL; PEPTIDOMIMETICS; PYRIDINES; PYRIMIDINES; RECEPTOR, ERBB-2; RECEPTORS, PROGESTERONE; SRC-FAMILY KINASES; THIAZOLES; TUBULIN MODULATORS; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84866096038     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0146     Document Type: Article

References (41)

1. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007;13:2329-34. (Pubitemid 46698581)
2. Rodler E, Korde L, Gralow J. Current treatment options in triple negative breast cancer. Breast Dis 2010;32:99-122.
3. Nabholtz JM, Gelmon K, Bontenbal M, Spielmann M, Catimel G, Conte P, et al. Multicenter, randomized comparative study of two doses of paclitaxel in patients with metastatic breast cancer. J Clin Oncol 1996;14:1858-67. (Pubitemid 26185461)
4. Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol 2010;7:683-92.
5. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2226-38. (Pubitemid 46424242)
6. Sakamoto M, Takamura M, Ino Y, Miura A, Genda T, Hirohashi S. Involvement of c-Src in carcinoma cell motility and metastasis. Jpn J Cancer Res 2001;92:941-6. (Pubitemid 32970434)
7. Schlessinger J. New roles for Src kinases in control of cell survival and angiogenesis. Cell 2000;100:293-6. (Pubitemid 30353084)
8. Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest 2011;121:2750-67.
9. Finn RS, Bengala C, Ibrahim N, Roche H, Sparano J, Strauss LC, et al. Dasatinib as a single agent in triple-negative breast cancer: results of an Open-Label Phase 2 Study. Clin Cancer Res 2011;17:6905-13.
10. Gucalp A, Sparano JA, Caravelli J, Santamauro J, Patil S, Abbruzzi A, et al. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer. Clin Breast Cancer 2011;11:306-11.
11. AnbalaganM, Carrier L, Glodowski S, Hangauer D, Shan B, Rowan BG. KX-01, a novel Src kinase inhibitor directed toward the peptide substrate site, synergizes with tamoxifen in estrogen receptor alpha positive breast cancer. Breast Cancer Res Treat 2012;132: 391-409.
12. Fallah-Tafti A, Foroumadi A, Tiwari R, Shirazi AN, Hangauer DG, Bu Y, et al. Thiazolyl N-benzyl-substituted acetamide derivatives: synthesis, Src kinase inhibitory and anticancer activities. Eur J Med Chem 2011;46:4853-8.
13. ClinicalTrial.gov [homepage on the Internet]. Identifier: NCT00658970. Available from: http://clinicaltrials.gov/ct2/show/NCT00658970. Jan 2008-June 2011.
14. ClinicalTrial.gov [homepage on the Internet]. Identifier: NCT01074138. Available from: http://clinicaltrials.gov/ct2/show/NCT01074138. Feb 2010.
15. ClinicalTrial.gov [homepage on the Internet]. Identifier: NCT01397799. Available from: http://clinicaltrials.gov/ct2/show/NCT01397799. July 2011.
16. Hangauer D, Smolinski M, Bu Y, Kazim AL, Qu J. Photoaffinity labeling studies to better define the mechanism of action for Phase II oncology drug KX2-391 [abstract]. In: Proceedings of the 239th ACS National Meeting; 2010 Mar 21-25; San Francisco, CA; 2010. Abstr nr MEDI 295.
17. Tryfonopoulos D, Walsh S, Collins DM, Flanagan L, Quinn C, Corkery B, et al. Src: a potential target for the treatment of triple-negative breast cancer. Ann Oncol 2011;22:2234-40.
18. Finn RS, Dering J, Ginther C, Wilson CA, Glaspy P, Tchekmedyian N, et al. Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro. Breast Cancer Res Treat 2007;105:319-26.
19. Bijman MN, van Nieuw Amerongen GP, Laurens N, van Hinsbergh VW, Boven E. Microtubule-targeting agents inhibit angiogenesis at subtoxic concentrations, a process associated with inhibition of Rac1 and Cdc42 activity and changes in the endothelial cytoskeleton. Mol Cancer Ther 2006;5:2348-57. (Pubitemid 44530472)
20. Lee GY, Kenny PA, Lee EH, Bissell MJ. Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 2007;4:359-65. (Pubitemid 46766981)
21. Becker M, Nitsche A, Neumann C, Aumann J, Junghahn I, Fichtner I. Sensitive PCR method for the detection and real-time quantification of human cells in xenotransplantation systems. Br J Cancer 2002;87:1328-35. (Pubitemid 36009141)
22. Lee RH, Pulin AA, Seo MJ, Kota DJ, Ylostalo J, Larson BL, et al. Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6. Cell Stem Cell 2009;5:54-63.
23. Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res 2010;70:440-6.
24. Yen WC, Lamph WW. The selective retinoid X receptor agonist bexarotene (LGD1069, Targretin) prevents and overcomes multidrug resistance in advanced breast carcinoma. Mol Cancer Ther 2005;4: 824-34. (Pubitemid 40767127)
25. Naumova E, Ubezio P, Garofalo A, Borsotti P, Cassis L, Riccardi E, et al. The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clin Cancer Res 2006;12:1839-49.
26. Hangauer D, Smolinski M, Bu Y, Teegarden P, Qu J, Kazim L, et al. Discovery of KX2-391: a phase II Src signaling inhibitor with a second MOA [abstract]. In: Proceedings of the Keystone Symposia, New directions in small molecule drug discovery; 2010 Apr 22; Whistler, British Columbia, Canada; 2010. p. 113, Speaker Abstr nr 13.
27. Rugo HS, Thomas ES, Lee RK, Fein LE, Peck R, Verrill M, et al. Combination therapy with the novel epothilone B analog, ixabepilone, plus capecitabine has efficacy in ER/PR/HER2-negative breast cancer resistant to anthracyclines and taxanes[abstract]. In: Proceedings of the SABCS; 2007 Dec 13-26; San Antonio, TX; 2007. Abstr nr 6069.
28. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355:2542-50. (Pubitemid 44917502)
29. Mayer EL, Krop IE. Advances in targeting SRC in the treatment of breast cancer and other solid malignancies. Clin Cancer Res 2010;16:3526-32.
30. Fornier MN, Morris PG, Abbruzzi A, D'Andrea G, Gilewski T, Bromberg J, et al.Aphase I study of dasatinib and weekly paclitaxel for metastatic breast cancer. Ann Oncol 2011;22:2575-81.
31. Yang H, Ganguly A, Cabral F. Inhibition of cell migration and cell division correlates with distinct effects ofmicrotubule inhibiting drugs. J Biol Chem 2010;285:32242-50.
32. Balzer EM, Whipple RA, Thompson K, Boggs AE, Slovic J, Cho EH, et al. c-Src differentially regulates the functions of microtentacles and invadopodia. Oncogene 2010;29:6402-8.
33. Frame MC, Fincham VJ, Carragher NO, Wyke JA. v-Src's hold over actin and cell adhesions. Nat Rev Mol Cell Biol 2002;3:233-45. (Pubitemid 34619259)
34. Buccione R, Caldieri G, Ayala I. Invadopodia: specialized tumor cell structures for the focal degradation of the extracellular matrix. Cancer Metastasis Rev 2009;28:137-49.
35. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, et al. Genes that mediate breast cancer metastasis to lung. Nature 2005;436:518-24. (Pubitemid 41112921)
36. Elias D, Di Pietroantonio D. Surgery for liver metastases from breast cancer. HPB (Oxford) 2006;8:97-9.
37. Stein U, Walther W, Arlt F, Schwabe H, Smith J, Fichtner I, et al. MACC1, a newly identified key regulator of HGF-MET signaling, predicts colon cancer metastasis. Nat Med 2009;15:59-67.
38. Marsden CG, Wright MJ, Carrier L, Moroz K, Pochampally R, Rowan BG. A novel in vivo model for the study of human breast cancer metastasis using primary breast tumor-initiating cells from patient biopsies. BMC Cancer 2012;12:10.
39. Chu I, Arnaout A, Loiseau S, Sun J, Seth A, McMahon C, et al. Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer. J Clin Invest 2007;117:2205-15. (Pubitemid 47219565)
40. Elsberger B, Tan BA, Mitchell TJ, Brown SB, Mallon EA, Tovey SM, et al. Is expression or activation of Src kinase associated with cancer-specific survival in ER-, PR- and HER2-negative breast cancer patients? Am J Pathol 2009;175:1389-97.
41. Dolle JM, Daling JR,White E, Brinton LA, DoodyDR, Porter PL, et al. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomarkers Prev 2009;18:1157-66.